Gastrointestinal Cancer Articles | Page 3

Molecular Testing Advancements Leading Field of GI Cancers
Shirley Michelle Shiller, DO, discusses progress with precision medicine for patients with gastrointestinal cancers.
Checkpoint Inhibitors, TKIs, and Novel Agents Poised to Enter Liver Cancer Treatment Paradigm
Ghassan K. Abou-Alfa, MD, discusses what he sees coming down the pike in epatocellular carcinoma with regard to novel agents, including CAR T-cell therapy, and the burgeoning questions with optimal sequencing of these treatments.
Questions Remain on Optimal mCRC Treatment
Leonard Saltz, MD, discusses current go-to therapies and overarching questions for mCRC treatment.
Surgery a Mainstay in Colorectal Cancer Treatment
William R. Jarnagin, MD, discusses the necessary role of surgery and novel techniques in patients with colorectal cancer.
CHMP Issues Positive Opinion on Herzuma for HER2+ Breast, Gastric Cancers
The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
Pembrolizumab Misses Endpoints in Phase III Gastric Cancer Trial
Pembrolizumab did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III KEYNOTE-061 trial.
Expert Says Clinical Trials Are Essential for Progress in Metastatic CRC
Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer. 
Solving the BRAF Mystery in CRC: Genomic Clues Lead to Triplets and Immunotherapy
Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.
Tanios Bekaii-Saab, MD, FACP, and Rona D. Yaeger, MD, discuss the current treatment landscape and other key issues relating to this distinct subset of colorectal cancer.
Adding ramucirumab to cisplatin and capecitabine or 5-FU in the frontline setting did not improve overall survival in patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, according to topline results from the phase III RAINFALL trial. 
Publication Bottom Border
Border Publication